BONVENTURE

BONVENTURE is a Munich-based impact investor that has spent years building a credible practice in the German-speaking part of Europe, also known as the DACH region, around the proposition that capital can compound while measurably improving social and health outcomes. The firm operates across Germany, Austria, and Switzerland, and within healthcare it focuses on digital health and tech-enabled care delivery. For founders building healthcare companies in the DACH region, BONVENTURE is one of the few investors that combines impact discipline with the operational seriousness of a traditional venture investor, and that combination is unusual enough to be worth understanding carefully.

The thesis is anchored in measurable impact, which BONVENTURE treats as a structural input to its investment process rather than a marketing layer. Within healthcare, the firm focuses on companies whose products demonstrably improve patient outcomes, expand access, or reduce the systemic cost of care, and it underwrites those outcomes with reporting frameworks that are genuinely consequential to the relationship rather than performative. The firm is comfortable with both pure software and tech-enabled services models, and it pays particular attention to companies whose impact can be defended with data rather than narrative. It tends to be skeptical of companies whose impact is incidental or whose business model creates a tension between commercial and outcome incentives. Within DACH digital health specifically, BONVENTURE engages with the realities of fragmented payer systems, reimbursement pathways such as the German Digital Health Application route, and the operational complexity of selling into hospital systems across three countries.

The portfolio includes LillianCare and Gardia, both of which are illustrative of the firm’s preference for companies that combine clear health-outcome theses with sustainable commercial models. Founders evaluating BONVENTURE should expect to be benchmarked against the operating discipline these companies represent: a clear primary outcome, a defined customer or payer, and a credible plan to expand without diluting the impact thesis. The firm is willing to underwrite a slower build cycle when the impact and clinical work justify it, and it is realistic about the time required to navigate DACH reimbursement and procurement processes.

Check sizes typically fall in the one to five million euro range, with the firm operating at seed and Series A. BONVENTURE will lead, co-lead, or participate, and it has the patience that the DACH healthcare market often demands. The reserve practice is consistent with a fund that intends to support companies through their first scaling phase, and founders should expect the firm to be a thoughtful participant in subsequent rounds.

Decision-making sits with the Munich-based partnership, which is small and operates with the cadence of an institutional impact-focused fund. Founders should expect direct engagement with senior partners and a process that takes the impact framework seriously, with reporting expectations established early in the relationship.

The right approach is a warm introduction from a portfolio founder, a DACH healthcare operator, or a co-investor with shared history in European impact investing. Cold outreach is acceptable when the founder can articulate a clear impact thesis with measurable outcomes and a realistic commercial plan. Founders should arrive prepared to discuss outcome measurement, reimbursement strategy, and how the company will operate across the DACH region’s three distinct healthcare systems.

What founders should know is that BONVENTURE is a fit for DACH healthcare founders who take impact seriously and who want a partner aligned on outcome measurement as well as financial returns. Founders looking for a pure-financial venture partner without an impact framework will find the relationship structurally different from a typical venture deal. Founders building digital health and tech-enabled care companies in the DACH region with credible impact theses will find BONVENTURE one of the most aligned early partners in the market.